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Did you know? 
•	 Annual economic losses as a result of ECF are 
valued at over USD 300 million.
•	 Nearly 60% of the region’s 75 million cattle are at 
risk of contracting ECF.
•	 In 1999, annual costs due to ECF in Kenya and 
Tanzania were estimated to be USD 95.1 million 
and USD 43.8 million, respectively.
•	 The ECF-ITM vaccine has been shown to be a 
highly effective product, with a 95% success rate 
in pastoral herds—one of the highest rates of 
protection offered by any livestock vaccine.  
•	 In northern Tanzania, calf mortality rates in 
pastoralist areas have been reduced from 80% 
to as low as 2% through use of the vaccine.
•	 ECF vaccine has been registered in Kenya, 
Tanzania and Malawi, and is being used with 
permission of Ugandan regulatory authorities 
whilst awaiting formal registration.
•	 Four distributors in Kenya, two in Uganda and 
two in Tanzania are delivering the ECF vaccine. 
East Coast fever (ECF), a tick-transmitted disease, causes 
major economic losses throughout eastern, southern and 
central Africa and is widely regarded as one of the most 
serious constraints to increasing the productivity of cattle 
in the region. The disease causes high mortality (>80%) and 
affects high-grade dairy cattle as well as young zebu cattle 
in pastoralist areas and ranches. For the past 40 years, 
ILRI’s research on ECF has focused on developing better 
methods of controlling the disease, principally through 
vaccination, and obtaining a far greater understanding of 
the impact of the disease. A vaccine is now registered 
in three countries and good protection for dairy and 
pastoralist cattle is being achieved, particularly in eastern 
Africa.
Context
Caused by the parasite Theileria parva and spread by 
the Rhipicephalus appendiculatus tick, ECF occurs in 11 
countries in eastern, southern and central Africa and kills 
over 1 million cattle every year. The disease is not only 
responsible for cattle deaths, but also results in stunting 
of calves and reduced milk production in animals that 
survive. At the household level, ECF results in reduced milk 
availability and incomes, undermining families’ food and 
nutrition security. And for smallholder dairy farmers with 
just one or two animals, the loss of a valuable cow can 
represent a devastating blow. In terms of indirect impacts, 
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where the disease is present, farmers may be discouraged 
from adopting more productive but highly susceptible 
breeds of cattle. Pastoralists are also forced to avoid areas 
of high ECF risk, something that is becoming increasingly 
difficult as the ticks and infected cattle move into new 
areas, further spreading the disease. 
ILRI’s approach
ECF is a significant economic burden for poor livestock 
keepers, particularly in African pastoral and agropastoral 
production systems, making it difficult for families to plan 
for the future, to improve their livestock enterprises and 
raise their standard of living.
Over the last hundred years, ECF control has been 
dominated by use of acaricides to limit tick infestations. 
These are applied as sprays, in dips and more recently 
as oil-based pour-ons. However, after prolonged use 
the ticks develop resistance to chemical treatments and 
few, if any, novel acaricides are in the process of being 
developed. Use of acaricides also exposes users to 
potential health risks, which are exacerbated by lack of 
protective clothing amongst the poor. The chemicals can 
also cause environmental contamination and frequent use 
of acaricides is expensive—in high ECF-challenge areas 
application might be needed every five or so days. 
In addition to this preventive approach, drugs are available 
for the treatment of ECF cases but, to be effective, they 
need to be used at an early stage of the disease. The cost 
per animal treated is also relatively high, especially for less 
valuable zebu cattle. 
An alternative control strategy through immunization 
(vaccination) has been available for several decades. Known 
as the ‘infection and treatment method’ (ITM), it involves 
inoculation with live T. parva parasites accompanied by 
an antibiotic treatment to prevent the infection taking 
hold. The animal experiences a mild infection (as with any 
vaccination) but develops a long-lasting immunity to the 
disease. 
First developed between 1967 and 1977 in Muguga, 
Kenya by the former East African Veterinary Research 
Organisation, the research on ITM involved multiple 
national, regional and international partners, including the 
International Laboratory for Research on Animal Diseases 
(ILRAD), now called ILRI. Various versions of the ITM 
vaccine have been developed, which differ in the strains 
of theilerial parasites in the vaccine. However, the most 
widely used version is known as the Mugaga cocktail, which 
comprises three isolates.
At the request of the UN Food and Agriculture 
Organization (FAO), ILRI produced the first commercial 
batch of the Muguga cocktail vaccine in 1996. A decade 
later, at the request of regional partners, ILRI produced 
the second commercial batch, which is now being used 
in eastern Africa. The production of the ECF vaccine is 
complicated, time-consuming and expensive (see Did you 
know?) The product then requires careful handling in order 
for it to be delivered via a cold chain and administered by 
trained vaccinators on farm.  
However, to date, over one million cattle have received 
the ITM vaccine produced by ILRI. With assistance from 
GALVmed, ILRI registered the vaccine in Kenya, Tanzania 
and Malawi, and progress has been made towards 
registration in Uganda. In Kenya, ILRI and KARI supported 
the Director of Veterinary Services in successful trials to 
confirm the safety and effectiveness of the Muguga cocktail-
based ITM vaccine, which led to the launch for national 
distribution in December 2012. 
The commercial production of the Muguga cocktail has 
now been taken up by the Centre for Ticks and Tick-
borne Diseases in Malawi, facilitated by GALVmed and 
the Bill and Melinda Gates Foundation. ILRI assisted in the 
establishment of the production in Malawi through the 
transfer of tick and parasite seed stabilates. GALVmed has 
also promoted the commercial distribution of the vaccine 
in Kenya, Tanzania, Uganda and Malawi.
Next steps
ILRI continues to play a role in the uptake of the ITM 
vaccine by providing technical advice. ILRI has also 
developed molecular tools to characterize parasite strains, 
which will be important in quality assurance of future 
vaccine productions. 
Although the live vaccine has been shown to be both safe 
and very effective, as mentioned above, the production of 
the vaccine and its delivery have considerable challenges. 
ILRI has therefore been engaged in research directed 
towards obtaining a better understanding of the immune 
response that protects cattle against ECF and in identifying 
Tick control and management against East Coast fever in Kenya (photo 
credit: ILRI).
ILRI Research Brief—September 2014 3
Success with pastoralists in Tanzania
Whilst scientists initially thought that the ECF vaccine 
would be of interest to commercial farmers only, 
relatively poor pastoralists in northern Tanzania have 
been willing to pay a relatively high price (up to USD 
10/animal) for the ECF vaccine. As a result, up to 80% 
of calves have been vaccinated each year since 1998 
across many wards, providing lifelong immunity against a 
disease which is responsible for half of calf deaths. ‘These 
are livestock keepers who know cattle and who know 
diseases,’ says Lieve Lynen of VetAgro Ltd., which has a 
network of community animal health workers to help 
in the vaccination program. ‘They are willing to adopt 
a technology if it works—to commit themselves to a 
product where they see it gives them a future in livestock 
production.’
As a result, vaccinated animals no longer have to avoid 
high risk ECF areas and vaccination campaigns have 
reduced the amount of acaricides needed for dipping or 
spraying cattle. The pastoralists report that cattle with the 
distinctive round ECF ear-tag attract higher prices than 
non-vaccinated animals of equal size and their increased 
incomes are being used to diversify their livelihoods and 
send more children, including girls, to school.
the parasite components responsible for provoking this 
immunity. ILRI is leading a recently established consortium 
of institutes engaged in aspects of this research. 
The hoped-for outcome is an alternative ‘sub-unit’ vaccine 
that will be cheaper and easier to produce and more ‘user-
friendly’ for those delivering the vaccine. Nevertheless, 
there are major technical obstacles to be overcome in the 
development of the ‘sub-unit’ vaccine, and such a vaccine is 
several years away. 
At the same time, research opportunities for improving the 
ITM vaccine exist. To identify the challenges in delivering 
the ITM vaccine and prioritize the research needed 
to overcome these challenges, ILRI recently cohosted, 
with GALVmed, a meeting of those involved in vaccine 
deployment—from manufacturers, directors of veterinary 
services and vaccine registration officials, to those 
delivering the vaccine in the field. 
Development of a ‘sub-unit’ vaccine or an improved ITM 
would be a valuable addition in the fight against this deadly 
disease.
Maasai in northern Tanzania pay for the East Coast fever vaccine (photo credit: ILRI/Stevie Mann).
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A Maasai boy with his cattle wearing ear tags, designating that they have been immunized against East Coast fever in Tanzania (photo credit: ILRI/Lieve 
Lynen).
This is one of a series of briefs documenting the impacts 
of ILRI’s research. 
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